H.C. Wainwright lowered the firm’s price target on Calidi Biotherapeutics to $2 from $11 and keeps a Buy rating on the shares following the Q4 report. The new target reflects a series of equity financing each quarter for the rest of the year, the analyst tells investors in a research note. The firm says Calidi shares are being weighed down by a financing overhang.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLDI:
- Calidi Biotherapeutics Issues Regulation FD Disclosure Notice
- Calidi Biotherapeutics Restructures Debt and Streamlines Finances
- Calidi Biotherapeutics Showcases Oncolytic Virotherapy Advances
- Calidi Biotherapeutics Resolves Dispute with Equity Settlement
- Calidi Biotherapeutics Resolves Stock Dispute with Physicians